Table 1 Main patient and tumour characteristics (n = 258)
Characteristics | |
|---|---|
Median age at diagnosis; years (range) | 50 (18–80) |
Histological type of primary tumour; n (%) | |
Ductal | 228 (88.4) |
Lobular | 21 (8.1) |
Other subtypes | 9 (3.5) |
Tumour subgroup; n (%) | |
ER-positive | 184 (71.32) |
PR-positive | 122 (47.29) |
HR-positive | 189 (73.3) |
HER2-positive | 26 (10.2) |
Triple negative | 58 (22.5) |
ECOG performance status (%) | |
0 | 73 (28.3) |
1 | 133 (51.6) |
2 | 46 (17.8) |
3 | 6 (2.3) |
Previous chemotherapy for (neo) adjuvant/advanced disease | |
Anthracyclines; n (%) | 244 (94.6) |
Taxanes; n (%) | 253 (98.1) |
Capecitabine; n (%) | 234 (90.7) |
Median prior lines of chemotherapy in the metastatic setting (range) | 4 (1–9) |
Best response under previous taxane therapy; n (%) | |
Complete response | 20 (7.8) |
Partial response | 112 (43.8) |
Stable disease | 78 (30.5) |
Progressive disease | 33 (12.9) |
Not evaluable | 13 (5.1) |
Missing | 2 |
Hormonal therapy | |
Prior hormonal therapy (HR+ tumours; n [%]) | 184 (97.3) |
Metastatic sites; n (%) | |
Visceral metastases | 223 (86.4) |
Liver | 174 (67.4) |
Node | 118 (45.7) |
Lung | 98 (38.0) |
Brain | 41 (15.9) |
Serous | 55 (21.3) |
Skin | 31 (12.0) |
Bone | 176 (68.2) |
Other sites | 26 (10.1) |